Cover Image
市場調查報告書

Sutro Biopharma, Inc.:產品平台分析

Sutro Biopharma, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 314851
出版日期 內容資訊 英文 34 Pages
訂單完成後即時交付
價格
Back to Top
Sutro Biopharma, Inc.:產品平台分析 Sutro Biopharma, Inc. - Product Pipeline Review - 2016
出版日期: 2016年02月29日 內容資訊: 英文 34 Pages
簡介

Sutro Biopharma, Inc. ha是開發為治療癌症的多功能抗體藥物複合體聯合治療與基於雙功能抗體之療法的生物製藥公司。

本報告提供Sutro Biopharma, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Sutro Biopharma, Inc.的基本資料

  • Sutro Biopharma, Inc.概要
  • 主要資訊
  • 企業資料

Sutro Biopharma, Inc.:&D概要

  • 主要的治療範圍

Sutro Biopharma, Inc.:評估

  • 各開發階段的開發中產品
  • 單劑產品

Sutro Biopharma, Inc.:開發中產品概況

  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Sutro Biopharma, Inc.:藥物簡介

  • Antibody for Cancer
  • Monoclonal Antibody Conjugated for Cancer
  • Monoclonal Antibody for Oncology
  • Synthetic Peptide for Undisclosed Indication
  • Mocolonal Antibody to Target GD2 for Neuroblastoma
  • Monoclonal Antibody to Target CD3 for Neuroblastoma
  • Monoclonal Antibody to Target GD2 for Melanoma
  • Monoclonal Antibody to Target GD2 for Osteosarcoma

Sutro Biopharma, Inc.:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

Sutro Biopharma, Inc.:最近的開發平台趨勢

Sutro Biopharma, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07978CDB

Summary

Global Markets Direct's, 'Sutro Biopharma, Inc. - Product Pipeline Review - 2016', provides an overview of the Sutro Biopharma, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sutro Biopharma, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Sutro Biopharma, Inc.
  • The report provides overview of Sutro Biopharma, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Sutro Biopharma, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Sutro Biopharma, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Sutro Biopharma, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sutro Biopharma, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sutro Biopharma, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Sutro Biopharma, Inc. Snapshot
    • Sutro Biopharma, Inc. Overview
    • Key Information
    • Key Facts
  • Sutro Biopharma, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Sutro Biopharma, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Sutro Biopharma, Inc. - Pipeline Products Glance
    • Sutro Biopharma, Inc. - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • Sutro Biopharma, Inc. - Drug Profiles
    • Monoclonal Antibodies for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates 1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates 2 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize CTLA4 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit LAG3 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit PD-1 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit PD-L1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit TIM3 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Target CD3 for Neuroblastoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Target GD2 for Melanoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Target GD2 for Neuroblastoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Target GD2 for Osteosarcoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Sutro Biopharma, Inc. - Pipeline Analysis
    • Sutro Biopharma, Inc. - Pipeline Products by Target
    • Sutro Biopharma, Inc. - Pipeline Products by Molecule Type
    • Sutro Biopharma, Inc. - Pipeline Products by Mechanism of Action
  • Sutro Biopharma, Inc. - Recent Pipeline Updates
  • Sutro Biopharma, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Sutro Biopharma, Inc., Key Information
  • Sutro Biopharma, Inc., Key Facts
  • Sutro Biopharma, Inc. - Pipeline by Indication, 2016
  • Sutro Biopharma, Inc. - Pipeline by Stage of Development, 2016
  • Sutro Biopharma, Inc. - Monotherapy Products in Pipeline, 2016
  • Sutro Biopharma, Inc. - Discovery, 2016
  • Sutro Biopharma, Inc. - Pipeline by Target, 2016
  • Sutro Biopharma, Inc. - Pipeline by Molecule Type, 2016
  • Sutro Biopharma, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Sutro Biopharma, Inc. - Recent Pipeline Updates, 2016
  • Sutro Biopharma, Inc., Other Locations

List of Figures

  • Sutro Biopharma, Inc. - Pipeline by Indication, 2016
  • Sutro Biopharma, Inc. - Pipeline by Target, 2016
  • Sutro Biopharma, Inc. - Pipeline by Molecule Type, 2016
  • Sutro Biopharma, Inc. - Pipeline Products by Mechanism of Action, 2016
Back to Top